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Abstract
Herstatin (HST) is an alternatively spliced HER2 product with growth-inhibitory properties in experimental cancer
systems. The role of HST in adult human tissues and disease remains unexplored. Here, we investigated HST ex-
pression at the mRNA and protein (immunohistochemistry [IHC]) level in parallel with parameters reflecting HER
activation in 187 breast carcinomas and matched noncancerous breast tissues (NCBT). Noncancerous breast tis-
sues demonstrated the highest HST/HER2 transcript ratios corresponding to a few positive epithelial and stromal
cells by IHC. Although HST/HER2 transcript ratios in tumors were inversely associated with HER2 IHC grading (P=
.0048 for HER2 IHC-1+ and P = .0006 for HER2 IHC-2+ vs HER2-negative tumors), relative HST expression within
the same tumor/NCBT system remained constant. HST/HER2 ratios did not predict the presence of HST protein,
which was found in 46 (25%) of 187 tumors. A subgroup of HER2 IHC-3+ tumors exhibited high HST/HER2 tran-
script ratios, strong HST protein positivity, and cytoplasmic phospho–Akt/PKB and p21CIP1/WAF1 localization. In
conclusion, HST may act as a paracrine factor in the adult breast. Because HST is described as an endogenous
pan-HER inhibitor, the presence of this protein in breast carcinomas may portent the inefficiency of exogenous
efforts to block HER2 dimerization, whereas its absence may justify such interventions.
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Introduction
Two decades ago, HER2/neu overexpression in approximately 30% of
breast carcinomas was first associated with adverse disease prognosis
[1], p185-HER2 overexpression proved transforming and tumorigenic
for cultured mouse fibroblasts [2], whereas a specific anti–185-HER2
antibody showed antiproliferative activity in vitro [3]. This basis
provided the rationale for the development [4] and clinical establish-
ment of trastuzumab in the treatment of breast cancer [5–7]. However,
resistance to trastuzumab is still the case in approximately 50% of
HER2-amplified/overexpressing tumors [5,6]. To overcome resistance
and to overall improve clinical outcome in targeted breast cancer treat-
ment, further combined use of anti-HER antibodies and kinase in-
hibitors has been proposed [8–11]. One such anti-HER monoclonal
antibody is 2C4 (pertuzumab) [12], which was designed to inhibit
HER2-dependent signaling in both HER2 low- and high-expressing
tumors. Pertuzumab binds HER2 extracellular domain (ECD) at an
area other than trastuzumab and inhibits HER2 dimer formation
and, hence, activation [13].
Interestingly, dominant-negative HER2 regulators with pertuzumab-
like properties are produced endogenously as well, in fact, as alter-
natively spliced products of the HER2 gene itself. At least two such
molecules have been identified and described as p68-HER2 and
p100-HER2 [14,15]. p68-HER2, the most advanced studied mole-
cule of these two, was initially called herstatin (HST) [15] and later
dimercept [16]. Herstatin mRNA is an alternatively spliced HER2
Abbreviations: HST, herstatin; NCBT, noncancerous breast tissue; IHC, immunohis-
tochemistry; FFPE, formalin-fixed paraffin-embedded
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product retaining intron 8; the translated protein is identical to HER2
ECDI and most part of ECDII with a unique carboxy-tail sequence
substituting for ECDIII [15]. With this tail, HST specifically binds
HER2 ECDII [17] in a way similar to pertuzumab [13], whereas it
also binds epidermal growth factor receptor (EGFR) andHER4, and less
insulin-like growth factor 1 receptor [18]. Herstatin is a soluble protein,
because it lacks a transmembranous domain and it can be secreted from
the cells it has been produced [15]. Herstatin specifically prevents
HER2/HER3 and HER2/EGFR dimer phosphorylation by disrupting
dimers formedwithHER2 [19], whereas it inhibits transforming growth
factor alpha– and EGF-stimulated proliferation [20] and heregulin-
dependent growth in breast cancer cells [21]. The same effects have
correspondingly been described for pertuzumab [13,22,23]. In the ex-
perimental therapeutic context, HSTexpression in glioblastoma cell im-
plants in female rats prevented intracranial tumor formation [24].
Currently, it is not known whether HST is expressed in adult human
tissues. If HST serves as an endogenous pan-HER “antibody,” cancers
would be expected to lack HSTexpression. If cancers express HSTand
still thrive, native HST production might not be effective in inhibiting
HER signaling. In this study, we investigated HSTmRNA expression
and protein presence in breast carcinoma tissues in parallel to their
normal counterparts, in association with HER2 IHC status and param-
eters reflecting downstream effects of HER activation, such as phosphor-
ylation of Akt/PKB and compartmentalization of p21Cip1/WAF1. The
latter two parameters were chosen on the basis of in vitro data showing
that activatedHER2 dimers on the cell membrane exert their cell growth
effects in part through Akt/PKB phosphorylation, which then phos-
phorylates and prevents the nuclear translocation of the cell cycle inhib-
itor p21Cip1/WAF1 [25]. At this state, both proteins are located in the
cytoplasm. At the tissue level, the subcellular localization of phosphor-
ylated Akt at Ser473 (pAkt) as detected by immunohistochemistry
(IHC) seems to be related with poor prognosis and response to therapy
in breast cancer [26,27]. HER2 overexpression is frequently associated
with pAkt [28,29] and with cytoplasmic p21Cip1/WAF1, which may be
used as a predictor of response to trastuzumab [30,31]. Although tested
on different cell systems, bothHST [20] and pertuzumab [23] were able
to block Akt/PKB phosphorylation.
In this study, we asked whether HST, the endogenous analogue of
pertuzumab, is produced in the adult breast and in breast carcinomas
and, if yes, in which association to established disease and to HER2
activation parameters. The study was performed on routine pathology
material, whereby special care was paid on sampling from cancer and
normal-appearing breast tissue. Real-time polymerase chain reaction
assays were designed for the specific detection of HST and the
corresponding area of HER2 transcripts, whereas a monoclonal anti-
body that specifically targets the carboxy-tail of HSTwas used for the
in situ detection of this protein. We found that HST transcripts and
protein are expressed in the noncancerous breast, where this molecule
may have a paracrine action and interfere with tissue homeostasis. In
breast carcinoma tissues, HSTmRNA levels do not predict for the
presence of the corresponding protein in 75% of cases, indicating that
cancer cells are protected by some regulatory mechanism from the
growth-inhibitory effects of this molecule. Most importantly, however,
if 25% of breast carcinomas grow in the presence of this endogenous
pan-HER inhibitor, which is produced in high amounts in some cases
with adverse prognostic parameters (HER2 overexpression, activated
Akt/PKB, and blocked p21CIP1/WAF1), then it remains questionable
whether these cancers would benefit from exogenous attempts to dis-
rupt HER dimerization.
Materials and Methods
Tissues
Previously diagnosed formalin-fixed paraffin-embedded (FFPE)
breast carcinoma tissues from 187 female patients were retrieved from
the archives of the Department of Pathology, School of Medicine,
Aristotle University, and from the Laboratory of Pathology, Theagenion
Cancer Hospital, according to the Declaration of Helsinki principles
and institutional review board policies. Patient and tumor data are
presented in Table 1. The term NCBTs (noncancerous breast tissue)
is used instead of normal throughout this study for morphologically
normal tissue adjacent to breast carcinomas. These structures have
recently been shown not to have undergone substantial changes
in their gene expression profile when compared to normal breast
tissue obtained from mammoplasty specimens [32]; hence, NCBT
is considered safe to use in comparative studies of tumor gene expres-
sion profiles.
Tissue Microarray Construction
Low-density tissue microarrays (TMAs; 14–16 cases per array) were
constructed with the Beecher manual tissue arrayer (Beecher Instru-
ments, Sun Prairie, WI). Seven cores from different areas in the same
breast carcinoma, along with three cores from matched noncancerous
breast tissue, were included from each case (core diameter, 0.6 mm).
Cores from normal skin and colon adenocarcinomas were also in-
cluded as controls and for block orientation.
RNA Extraction and Reverse Transcription
Tissue fragments were manually microdissected from cancerous
and NCBT areas corresponding to those included in the TMA cores
in 70 cases. These cases were selected on the basis of the content of at
least one normal-appearing ductal unit and surrounding epithelial
Table 1. Patient Data, Tumor Histologic Diagnosis, and Conventional Markers.
Age <50 years 49 26.2%
>50 years 106 56.7%
Unknown 32 17.1%
Tumor size <1 cm 5 2.7%
>1 cm 128 68.4%
Unknown 54 28.9%
Lymph nodes 0 25 13.4%
1 16 8.6%
>1 42 22.4%
Unknown 104 55.6%
Histologic diagnosis NOS 147 78.7%
Lobular 17 9.1%
Medullary 3 1.6%
Mucinous 7 3.7%
Anaplastic/squamous 1 0.5%
Mixed subtypes 9 4.8%
Mixed 3 1.6%
Tumor grade I 10 5.4%
II 73 39%
III 104 55.6%
ER Negative 73 39%
Low 27 14.5%
Medium 39 20.9%
High 48 25.6%
HER2 Negative 55 29.4%
1+ 59 31.6%
2+ 40 21.4%
3+ 33 17.6%
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tissue that could be safely, manually microdissected without contami-
nation of cancer infiltrates. RNAwas extracted on overnight proteinase
K digestion with TRIZOL-LS (Invitrogen, Paisley, UK).
Reverse Transcription–Polymerase Chain Reaction for the
Detection of HST and HER2 Transcripts
Random hexamers and Superscript II with an additional RNase H
(all from Invitrogen) incubation step were used for first-strand cDNA
synthesis. Primers, probes, and the rationale for protocol designing are
shown in Figure 1a. Of note, the HER2 product with spliced intron
8 does not necessarily correspond to the fully spliced mRNA from
NM_004448.2, because more splice variants have been described
concerning regions corresponding to or flanking the transmembranous
domain [14,33]. Initial screening of all samples for HST and HER2
transcripts was performed with simple reverse transcription–polymerase
chain reaction (RT-PCR) and Ready-To-Go PCR beads (Amersham,
Piscataway, NJ). The 165-bp HST product (Figure 1b) was validated
by sequencing. For relative quantification with real-time PCR, HST,
HER2, and ACTB (β-actin, housekeeping gene) targets were am-
plified with the corresponding TaqMan probes during 45 cycles at
95°C – 15 seconds at 60°C – 1 min in an ABI7500 sequence detection
system (Applied Biosystems, Biosolutions, Athens, Greece). Standard
curves for HST,HER2, and ACTB showing acceptable PCR efficiency
for all targets were obtained by using a cDNA template from anHER2
1+ breast carcinoma. Standard dilutions were prepared at 100, 50, 5,
and 0.5 ng of cDNA per reaction. Corresponding slopes of the curves
were as follows: ACTB, −3.4; HER2, −3.6; and HST, −3.4; and
corresponding R2 values were as follows: ACTB, 0.99; HER2, 0.99;
and HST, 0.98.
Relative quantification of HST versus ACTB and HER2 in tumor
versus pooled and separately paired NCBT samples was assessed with
the SDS v1.3 software, which uses the 2−ΔΔC t method [34]. In addi-
tion, the 2−ΔC t method [34] was used to assess HST/HER2 transcript
ratios in the same sample on the basis of equal efficiencies for the
amplification of PCR targets. Samples were normalized to contain ap-
proximately 50 ng of cDNA per reaction. The reading threshold was
set at 0.08, and the relative quantification minimum/maximum con-
fidence interval was at 99.9%. Runs were repeated at least twice for
all samples.
Immunohistochemistry for HST
The CW001 monoclonal antibody (Upstate Biotechnology, Lake
Placid, NY), which has been raised against the characteristic HST
protein carboxy-tail, was used at a 1:75 dilution. Antigen retrieval
was accomplished with proteinase K for 5 min at room temperature.
Binding was developed with the Envision system (DAKO, Carpinteria,
CA) and visualization with diaminobenzidine (DAKO). Negative
controls to assess specificity of staining included (i) preabsorption
of CW001 with recombinant HST protein (generously supplied by
BioVendor, Brno, Czech Republic) in PowerBlock, (ii) addition of a
universal antimouse-negative control antibody (DAKO), and (iii)
omission of primary antibody during overnight incubation. The
IHC protocol was standardized on whole-breast sections including
tumor and normal areas.
Immunohistochemistry for HER2-Related Targets
Immunohistochemistry for estrogen receptor alpha (ERα) and
for HER2 intracellular domain (HercepTest; DAKO, Glostrup,
Figure 1. Design of the real-time PCR assays that were used for the investigation of HST expression in breast carcinomas. (a) Specific
primers and probes were designed for the detection of HST (165-bp product retaining intron 8) and HER2 (150-bp product lacking intron
8, probably corresponding to HER2 receptor) mRNA targets. The sense HST primer includes an S corresponding to the silent G/C mis-
match in exon 7 (AF_177761 and NM_004448), which in two of three sequenced cases proved to be a G. Theoretically, a 424-bp product
corresponding to HST transcripts would coamplify with the wild type HER2 target; this, however, could not be observed in the FFPE
samples. Sequences are shown in 5′–3′ sense direction. (b) Representative RT-PCR results for matched NCBT/tumor pairs are shown.
Specific HST products are detected in the presence of HER2.
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Denmark) was performed in an automated system according to stan-
dard diagnostic protocols. Clone MIB-1 (DAKO, Carpinteria, CA)
was used for the evaluation of tumor proliferation status. To assess
HER activation status, monoclonal antibodies against phosphorylated
Akt/PKB (pAkt-S473; Cell Signaling Technologies, Beverly, MA) and
p21CIP1/WAF1 (DAKO, Carpinteria, CA) were used. A tryptase stain-
ing had to be used for the validation of mast cells.
Immunohistochemistry Evaluation
There is currently no reference on how to evaluate HST IHC on
naive tissues. Staining was evaluated under medium (×200) and high
(×400) power. Tumors were considered negative when no HST-
specific intracytoplasmic staining was observed in the neoplastic cells
on any core. A cutoff of 25% was used to evaluate low and high HST
positivity, because, although most positive tumors exhibited HST-
specific staining in single cells (<25%, low HST), in some tumors,
strong staining in 30% to 70% (>25%, high HST) of neoplastic cells
was repeatedly observed. The status of Akt/PKB phosphorylation
was evaluated as negative (absence of staining), nuclear (exclusively
nuclear staining in >50% of cells), and positive (staining in the cyto-
plasm only, or in both cytoplasm and nuclei). Staining for p21CIP1/WAF1
was evaluated as negative (absence of staining), nuclear (presence in
the nucleus only), and cytoplasmic (exclusively cytoplasmic or nuclear
and cytoplasmic). MIB-1 labeling index was assessed as the percent-
age of positive tumor cells in all cores under medium power (×200).
For the assessment of each tumor, staining in all cores was assessed. If
less than five of seven cores were available on TMA sections per tu-
mor, cases were considered as inadequately represented and were not
further evaluated.
Statistics
Statistical analyses were performed with the SPSS software (v14;
SPSS, Inc, Chicago, IL). Spearman’s Rho was used to correlate rela-
tive quantification results. The Mann-Whitney test was used for the
comparison of relative quantification values versus IHC results; the
same test was used to evaluate IHC results between subgroups of
markers, whereas the Kruskal-Wallis test was used to evaluate the
overall impact of IHC staining profiles among qualitative markers.
Results
HST mRNA Is Expressed in NCBT and Breast Carcinomas
All 70 tumors but only 63 of 70 NCBT samples yielded ampli-
fiable templates for PCR. Herstatin transcripts were identified by
simple RT-PCR in 58 (92%) of 63 NCBT and in 55 (78.6%) of
70 tumor samples (Figure 1b), always in the presence of HER2 tran-
scripts. Reliable amplification curves (cycle threshold [C t] < 40) were
detected with real-time PCR in 63 (100%) of 63 amplifiable NCBTs
and in 61 (92.9%) of 70 tumor samples.
HST Expression in Breast Carcinomas Is Related to HER2
mRNA and Protein Expression
Relative HER2 values versus ACTB were fairly constant among
NCBTs, ranging from 0.2043 to 1.399 (mean ± SD 1.017 ±
0.5285), comparable to previous reports [35]. By contrast, relative
HST values versus ACTB varied extensively among NCBTs (>3 log
orders); hence, all relative quantification analyses were assessed in
matched tumor/NCBT pairs (n = 61). In these sample pairs, relative
HST expression positively correlated to that of HER2 (Spearman’s
rank test, P < .00001), whereas both relatively high HST and
HER2 expression were associated with HER2 IHC (Figure 2). Rel-
ative HST/HER2 ratios within the same tumor/NCBTmilieu, how-
ever, did not differ on HER2 IHC grading (P = .531).
Individual samples expressed less HST than HER2 transcripts,
because HST/HER2 ratios were always <1 in the same sample (Fig-
ure 3). HST/HER2 ratios in individual tumor samples varied accord-
ing to HER2 IHC grading.
HST/HER2 ratios were generally higher in NCBTs than in the
matched tumors (Figure 3a), but this did not reach statistical signif-
icance. However, NCBTs adjacent to HER2 IHC grade 3+ tumors
expressed very low HST levels in half the cases of this tumor cate-
gory. Although individual tumor groups are small (Figure 3a) and the
analysis is prone to statistic errors, these results show that HST/
HER2 ratios in tumors differed according to HER2 grade but not
according to HST immunopositivity. In addition, these results fur-
ther support that HST/HER2 ratios among tumor/NCBT systems
were independent of HER2 IHC grading, as mentioned previously.
This can be particularly observed in HER2-overexpressing cases,
where high HST/HER2 ratios in tumors were accompanied by
low HST/HER2 ratios in the corresponding NCBTs and vice versa
(Figure 3a).
HST Protein Detection by IHC and Its Association with
Relative HST Expression
Currently, there are no reference data on HST protein presence in
naive tissues, hence an established positive reference was not avail-
able. Herstatin staining proved specific, because besides conventional
negative controls, incubation with the recombinant HST protein after
preabsorption with the CW001 anti-HST antibody resulted in the
disappearance or marked fainting of staining (Figure 4, b and d ).
Figure 2. Both HST and HER2 are overexpressed in HER2 IHC 3+
tumors. Relative HER2 and HST expression in tumor versusmatched
NCBT pairs with ACTB as the endogenous reference is shown in a
series of 24 cases. Herstatin relative quantification values ranged
from 0.012 to 16,949.78 (mean ± SD, 428.21 ± 2413.54), in a sim-
ilar log range to those of HER2 (range, 0.027–23469.40; mean ±
SD, 640.86 ± 3335.93). Relative HER2 and HST expression values
versus ACTB strongly correlated with HER2 IHC and were signifi-
cantly higher in HER2-overexpressing tumors than in all other
HER2 grading categories (Mann-Whitney, P < .00001 for both
HER2 and HST).
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Herstatin protein was observed mainly in the cytoplasm, seldom
on cell membranes, and never in the nuclei, while it was also present
in the cytoplasm of stromal mast cells and as fine granules diffusely in
the stroma (Figure 4, a and c), in line with the soluble nature of this
protein [15]. Herstatin-positive mast cells were observed in all
NCBTs, except for those in the neighborhood of HER2–3+/HSThigh
tumors. Positive mast cells were also observed in the stroma of 80
(42.7%) of 187 tumors, unrelated to HST staining in tumor cells.
Figure 3. HST/HER2 ratios within the same tumor distinguish two subgroups in HER2-overexpressing tumors with specific AKT/PKB ac-
tivation profiles. (a) Mean values and statistically significant differences in the different tumor subgroups show that the ratio of HST versus
HER2 transcripts declines with increasing HER2 expression. However, there is one subgroup of HER2 3+ tumors that overexpress HST.
The NCBT counterparts of these tumors practically lack HST expression. (b) Artificial heatmap showing the associations of HST/HER2
ratios in tumors and matched NCBTs with HST immunopositivity, as well as with AKT/PKB activation profile. Cases have been grouped
according to their HER2 status as assessed with IHC. The highest HST/HER2 ratios were observed in NCBTs and in HER2 IHC-negative or
grade 3+ tumors. HST/HER2 ratios were significantly low in HER2 IHC grade 1+, 2+, and in the remaining HER2 IHC grade 3+ tumors.
Note the difference in the total profile between HER2high/HSTlow and HER2high/HSThigh tumors.
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In NCBTs, faint HST staining was detected in ductal epithelial cells,
some capillary endothelia, and seldom in lobular units and myo-
epithelial cells (Figure 4e).
Although HST transcripts were found in most tumor tissue samples,
HST protein could be detected in the neoplastic cells of only 46
(24.6%) of 187 tumors with immunopositivity usually confined to
<25% of tumor cells (36/46 [78.2%] HST-positive cases). Herstatin-
positive cells were distributed evenly among negative ones without focal
accumulation, as observed during staining standardization on whole
sections. The HST positivity pattern in tumors was comparable to
NCBTs, but the staining intensity in tumors was stronger (Figure 4a).
Herstatin immunopositivity in tumor cells was generally not associated
with tumor HST/HER2 ratios (Table 2). The only cases where HST
IHC fully corresponded to HST/HER2 ratios were HER2high/HSThigh
tumors (P = .0020 between the two HER2 IHC-3+ subgroups). In
these cases, HST/ACTB ratios and HST relative expression versus
matched NCBTs were significantly high (P = .0283).
HST Immunopositivity Is Associated with HER2
Status and Cytoplasmic Localization of Phosphorylated
Akt/PKB and p21CIP1/WAF1
Statistically significant associations of the IHC results from this
study are presented in Table 2, a–c. Herstatin positivity in tumor
cells was not associated with patient age, ER and lymph node status,
tumor size and grade, MIB-1 labeling index, whereas it was strongly
associated with HER2 protein expression and Akt/PKB phosphory-
lation, and marginally with cytoplasmic localization of p21CIP1/WAF1
(Table 2 a). The lowest incidence of HST-positive tumors was ob-
served in the HER2 IHC-2+ group (13.5%) and the highest in the
group of HER2-overexpressing tumors (50%, P = .0015). In addition,
whereas HST positivity was observed in only 10.5% of tumors with-
out detectable Akt/PKB activation, it was present in 37.5% of tumors
with cytoplasmic pAkt-Ser473 localization (PMann-Whitney = .0001).
HER2 grading was unrelated to MIB-1, inversely associated with
ER status (P = .0009), as already established, and showed one-sided
association with cytoplasmic p21 and pAkt-Ser473 (Table 2 b). In
turn, pAkt-Ser473 was overall significantly associated with the expres-
sion of p21CIP1/WAF1 (Table 2 c), especially in terms of cytoplasmic
p21CIP1/WAF1 localization (PMann-Whitney = .0004). Interestingly, all
HER2–3+/HSThigh tumors that showed >25% HST immunopositiv-
ity were also positive for cytoplasmic pAkt-S473 and p21CIP1/WAF1
(Figures 3b and 5).
In comparison, when present, pAkt-S473 was localized in the nu-
clei of NCBT epithelial cells; p21CIP1/WAF1 was also observed in the
nucleus, although very rarely.
Discussion
Herstatin a soluble truncated HER2 variant that acts as a pan-HER
inhibitor, has been considered as a growth regulator during normal de-
velopment, because it is expressed in fetal kidney and liver tissues
[15], whereas its interference with HER dimer activation may disturb
proper hart valve formation [36] and impair cartilage and bone devel-
opment [37] in experimental models. In this study, we show that HST
mRNA and protein are expressed in the noncancerous breast, in areas
adjacent to breast carcinomas. In normal epithelial cells, low relative
HER2 levels are expressed [35] and correspond to approximately 2
to 4 × 104 HER2 molecules per cell [38] that translate into negative
or faint HER2 immunostaining. According to the high HST/HER2
ratios in most NCBTs (up to 25% of HER2 transcripts), the number
of HST transcripts described here would then be approximately
200 per cell. It seems that at the tissue level, HST is produced by few
epithelial and endothelial cells, whereas, as a soluble protein [15], it
may also accumulate in mast cells, suggesting a paracrine action as
well. This characteristic pattern of HST expression in NCBTs might
contribute to the normally effective endogenousHER-inhibition system
Figure 4. HST protein detection by IHC. (a–d) Testing on tissue sections for the specificity of the anti-HST antibody (CW001 clone,
staining in panels (a) and (c)) with preabsorption of the antibody with recombinant HST protein (mass ratio of 1:5, overnight incubation
at 4°C, markedly reduced or absent staining in (b) and (d)). (a and b) Same area of a HER2 IHC-2+ breast carcinoma; (c and d) same area
of the corresponding NCBT. Herstatin staining is specific in the cytoplasm and perinuclear area of tumor cells (a) and in mast cells
mostly observed around noncancerous breast elements (c). (e) Staining for HST protein in the cytoplasm of NCBT is faint but specific,
as observed under high magnification. Asterisks in panels (a)–(e) point at mast cells. Arrows in panel (e) point at positive epithelial cells;
arrowhead, positive endothelial cell. Scale bars, 50 μm.
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[39], because there is a local need for HER inhibition in differentiating
ductal epithelia [40].
HST/HER2 transcript ratios in tissues were comparable but gen-
erally lower than those described in cell lines [15], a result probably
due to tissue cell heterogeneity. HST/HER2 transcript ratios in
breast tumors inversely correlated with HER2 protein expression.
However, HST/HER2 ratios of 2% in HER2-negative, 0.8% in
HER2 – IHC 1+ and 0.5% in HER2 – IHC 2+ tumors reflect an
almost constant niveau of HST expression in tumors without overt
HER2 overexpression, given the corresponding rise in HER2 tran-
scripts. The trend toward equilibrium of HST/HER2 expression
was further noticed among the entire group of 63 tumor/NCBT
matched pairs examined, including tumor/NCBT pairs in HER2-
overexpressing cases. This finding may indicate that increased HST
expression is prevented in breast tissues in order not to disturb vital
for homeostasis growth factor signaling through the HER receptor
system [41] as would be expected from the high affinity with which
functional HST binds to its targets [15,18–21].
Unlike the situation in cell lines [15], HSTmRNA levels in tumors
were, in most cases, not predictive of HST protein presence. This was
more pronounced in HER2high/HSTlow tumors, where values of 0.5%
would evidently correspond to a higher number of molecules than that
observed in NCBTs. The possibility that few HST-positive cells might
have been missed due to poor representation of tumor tissue on the
TMA cores seems unlikely, because multiple areas from each tumor
were examined, whereas, as described, HST-positive cells were distrib-
uted throughout the tumor tissue. Whether HSTmRNA does not
reach the translation point due to posttranscriptional inhibitory in-
terference or whether this soluble protein is produced but escapes to
the circulation remains unknown. About the latter option, circulating
HER2 ECDmolecules are currently routinely measured (for example,
[42–45]) by an FDA-approved ELISA system [46] that was patented
back in 1991 [47]. The system detects HER2 molecules of 95 to
115 kDa including the entire ECD, but it cannot distinguish whether
these are produced by proteolytic shedding from the full-length receptor
[48] or as translated proteins from alternatively spliced products [14,33],
which could also escape into the circulation because they are soluble. All
versions of this systemhave used two antibodies,NB-3 andTA-1, which
Figure 5. HST/pAKT/p21CIP1/WAF1 profiles in HER2-overexpressing tumors. All photomicrographs are of the same magnification (scale
bar, 50 μm). In the HER2high/HSThigh tumor in panel (a), most neoplastic cells are positive for HST protein; pAKT and p21
CIP1/WAF1 are
localized in the cytoplasm, whereas the HST/HER2 transcript ratios are high in the tumor and low in the adjacent NCBT sample. In the
HER2high/HSTlow tumor in panel (b), HST, pAKT, and p21
CIP1/WAF1 are not detected, whereas HST/HER2 transcript ratios in the
corresponding tumor and NCBT samples are inverse in comparison to that observed in panel (a).
Table 2. HST Immunopositivity Strongly Correlates with pAkt But Only Marginally with
p21CIP1/WAF1 Status (a).
(a) Total* (%) HST P†
Negative <25% ≥25%
HER2
Negative 55/187 (29.4) 45 9 1
1+ 59/187 (31.6) 47 10 2 .0066 (HER2 vs HST)
2+ 40/187 (21.4) 35 5 0 .2778 (HST vs HER2)
3+ 33/187 (17.6) 17 9 7
pAkt
Negative 67/169 (39.6) 60 7 0 .0005 (pAkt vs HST)
Nuclear 38/169 (22.5) 25 12 1 .0002 (HST vs pAkt)
Cytoplasmic 64/169 (37.9) 40 15 9
p21CIP1/WAF1
Negative 54/169 (32) 45 7 2 .046 (HST vs p21)
Nuclear 77/169 (45.6) 58 13 6 .0639 (p21 vs HST)
Cytoplasmic 38/169 (22.4) 23 8 7
(b) Total* (%) HER2 P†
Negative 1+ 2+ 3+
pAkt
Negative 71/173 (41) 21 15 27 8 .0002 (HER2 vs pAkt)
Nuclear 38/173 (22) 10 15 5 8 .8309 (pAkt vs HER2)
Cytoplasmic 64/173 (37) 22 21 5 16
p21CIP1/WAF1
Negative 57/173 (33) 20 12 17 8 .0077 (HER2 vs p21)
Nuclear 77/173 (44.5) 25 24 15 13 .1723 (p21 vs HER2)
Cytoplasmic 39/173 (22.5) 6 16 5 12
(c) Total* (%) pAkt P†
Negative Nuclear Cytoplasmic
p21CIP1/WAF1
Negative 57/170 (33.5) 31 11 15 .0016 (pAkt vs p21)
Nuclear 76/170 (44.7) 30 19 27 .0011 (p21 vs pAkt)
Cytoplasmic 37/170 (21.8) 7 8 22
HER2 status in (a) and (b) is strongly associated with all parameters tested but only one-sided,
whereas cytoplasmic pAkt (c) strongly correlates with cytoplasmic p21CIP1/WAF1.
*Total number of cases for each marker pair vary due to availability of tissue on TMAs.
†Kruskal-Wallis test significance (asymptotic, one-sided); for each set of parameters, P is presented
in both directions. Significant associations are in bold.
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recognize different epitopes on HER2 ECD [47]. Because these
epitopes have not been described, it cannot be excluded (unless proven
otherwise) that circulating HSTmolecules are detected by this system as
well. In this context, it seemsworthy to assess the presence ofHST in the
circulation by HST-specific detection methods. Herstatin with its
unique carboxy-tail represents, in fact, a rare example of a splice variant
involved in a major signaling pathway for which specific antibodies can
be raised, such as the one used in the present study.
Most unexpectedly, approximately 1/5 of HER2-overexpressing
tumors were found to express relatively high HST/HER2 mRNA
ratios and to be strongly positive for HST protein. In comparison,
the NCBTs next to these tumors produced the lowest levels of
HST encountered in this study, a finding further supporting a para-
crine role for HST in breast tissue and, perhaps, a paracrine regula-
tory mechanism. This tumor group further exhibited a unique profile
of strong cytoplasmic phospho–Akt/p21CIP1/WAF1 protein positivity,
which, in the presence of HER2 overexpression, has been associated
with adverse prognosis in breast cancer and poor response to therapy
[26–31,49–51].
In addition, a strong bidirectional association between HST pro-
tein and activated Akt/PKB was observed throughout the tumor se-
ries examined in this study. It must be noted that with the commonly
used antibody for the demonstration of activated Akt/PKB with
IHC, which was used here as well, it is possible to detect not only
phosphorylated Ser473 on Akt1 but also the corresponding serines
on Akt2 and 3. Hence, it is impossible to distinguish which Akt is
phosphorylated. It is known that all three Akt isoforms, which may
have distinct roles in cancer progression [52,53], are produced in
breast cancer [54], where they have mainly prosurvival [55] and
questionable cell migration effects [56]. The antibody used detects
pAkt-S473 in the cytoplasm, cell membrane, and nucleus. Although
the presence of pAkt in the nucleus may be important for cancer pro-
gression because it seems related to MDM2 phosphorylation and
p53 inactivation [57,58], nuclear compartmentalization of pAkt
may also be detected in normal breast epithelial cells, as we have
observed here. Nevertheless, because the previously mentioned lit-
erature data on pAkt in breast cancer are based on the evaluation
of cytoplasmic staining [26–31,50], we considered this subcellular
localization of Akt/PKB as the prosurvival and poor prognosis indi-
cator. The simultaneous presence of cytoplasmic p21CIP1WAF1 and
pAkt, which further suggests a growth advantage for the tumors
[25,31,59], was also marginally associated with the presence of
HST. Because HST has been described to block EGF/EGFR–
induced Akt/PKB phosphorylation and proliferation in vitro [20],
the previously mentioned findings could be interpreted as an attempt
by the HST-positive cancer cells to block Akt/PKB phosphorylation.
Anti-HER antibodies such as 2C4 or the newly developed Mab806
seem not to necessitate an active conformation of the receptor to
achieve its internalization [60]. In our cases, no correlation was ob-
served for HST versus membranous EGFR and EGFR-Y992; there
was a vague association between HST and EGFR phosphorylation
at Tyr1068 (our unpublished data). In all, however, the fact that
tumors grow although they may express high levels of HST reflects
the inefficiency of this molecule to inhibiting tumor growth in vivo.
Alternatively, strong cytoplasmic HST localization may indicate
that this protein is impaired from exiting the cells by some as yet
unknown mechanism and, hence, it cannot bind to the extracellular
domain of HER receptors and exert its inhibitory action. If such
an export-inhibitory regulation is proven for tumors with strong
cytoplasmic HST, then these tumors might benefit from external
HST administration.
Whether HST (or dimercept) will ever enter clinical trials, as pre-
viously observed [16,24], remains unknown, especially because the
idea seems abandoned [61]. Published results from corresponding
testing of its manufactured “analogue,” pertuzumab, at least indicate
the necessity of combination agents to achieve disease remission [62–
64]. As we show here, although practically all tumors express HST
mRNA, this protein is absent in 75% of breast carcinomas, which
indicates that cancer cells are protected by some intrinsic mechanism
against the putative growth-inhibitory effects of this molecule. If this
negative regulation occurs at the pretranslational level, then it seems
possible that exogenous administration of pan-HER antibodies
would help block tumor growth. If the protein is produced but ex-
creted from the cells, then it seems possible that the mechanism,
which does not allow the endogenous inhibitor to act, will also
apply to the exogenous administered antibody as well. Most im-
portantly, if 25% of breast carcinomas grow in the presence of an
endogenous pertuzumab-like inhibitor, which is produced in high
amounts in some cases with adverse prognostic parameters (HER2
overexpression, activated Akt/PKB, and blocked p21CIP1/WAF1), then
it remains questionable whether these cancers would benefit from ex-
ogenous attempts to disrupt HER2 dimerization. These findings
need to be considered in the frame of clinical testing of pan-HER–
inhibitory antibodies with similar biologic effects to HST in the ex-
perimental setting.
Acknowledgments
The authors thank C. and N. Mitsiades for supplying most of the
reagents used in this study. We also thank Emily Daskalaki for excel-
lent technical assistance.
References
[1] Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL
(1987). Human breast cancer: correlation of relapse and survival with amplifi-
cation of the HER-2/neu oncogene. Science 235, 177–182.
[2] Hudziak RM, Schlessinger J, and Ullrich A (1987). Increased expression of the
putative growth factor receptor p185HER2 causes transformation and tumori-
genesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84, 7159–7163.
[3] Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, and Ullrich A
(1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro
and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol
9, 1165–1172.
[4] Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland
AM, Kotts C, Carver ME, and Shepard HM (1992). Humanization of an anti-
p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89,
4285–4289.
[5] Baselga J, Perez EA, Pienkowski T, and Bell R (2006). Adjuvant trastuzumab: a
milestone in the treatment of HER-2–positive early breast cancer. Oncologist 11
(Suppl 1), 4–12.
[6] Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith
I, Gianni L, Baselga J, Bell R, Jackisch C, et al. (2005). Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer. N Engl J Med 353, 1659–1672.
[7] Slamon D and Pegram M (2001). Rationale for trastuzumab (Herceptin) in ad-
juvant breast cancer trials. Semin Oncol 28, 13–19.
[8] Bilancia D, Rosati G, Dinota A, Germano D, Romano R, and Manzione L
(2007). Lapatinib in breast cancer. Ann Oncol 18 (Suppl 6), vi26–vi30.
[9] Engel RH and Kaklamani VG (2007). HER2-positive breast cancer: current and
future treatment strategies. Drugs 67, 1329–1341.
[10] Meric-Bernstam F and Hung MC (2006). Advances in targeting human epidermal
growth factor receptor-2 signaling for cancer therapy.Clin Cancer Res 12, 6326–6330.
[11] Nahta R, Yu D, Hung MC, Hortobagyi GN, and Esteva FJ (2006). Mecha-
nisms of disease: understanding resistance to HER2-targeted therapy in human
breast cancer. Nat Clin Pract Oncol 3, 269–280.
694 Herstatin in Breast Carcinomas Koletsa et al. Neoplasia Vol. 10, No. 7, 2008
[12] Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren
JA, Tindell C, Evans DP, Maiese K, et al. (2002). Targeting ligand-activated
ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2,
127–137.
[13] Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, and Sliwkowski
MX (2004). Insights into ErbB signaling from the structure of the ErbB2-
pertuzumab complex. Cancer Cell 5, 317–328.
[14] Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz CC, and Czubayko F
(2001). Expression of a truncated 100 kDa HER2 splice variant acts as an en-
dogenous inhibitor of tumour cell proliferation. Oncogene 20, 2101–2111.
[15] Doherty JK, Bond C, Jardim A, Adelman JP, and Clinton GM (1999). The
HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc
Natl Acad Sci USA 96, 10869–10874.
[16] Stix G (2006). Blockbuster dreams. Sci Am 294, 60–63.
[17] Hu P, Feng J, Zhou T, Wang J, Jing B, Yu M, Hu M, Zhang X, Shen B, and
Guo N (2005). In vivo identification of the interaction site of ErbB2 extracel-
lular domain with its autoinhibitor. J Cell Physiol 205, 335–343.
[18] Shamieh LS, Evans AJ, Denton MC, and Clinton GM (2004). Receptor binding
specificities of herstatin and its intron 8–encoded domain. FEBS Lett 568, 163–166.
[19] Azios NG, Romero FJ, Denton MC, Doherty JK, and Clinton GM (2001).
Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation
of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Oncogene
20, 5199–5209.
[20] Justman QA and Clinton GM (2002). Herstatin, an autoinhibitor of the
human epidermal growth factor receptor 2 tyrosine kinase, modulates epidermal
growth factor signaling pathways resulting in growth arrest. J Biol Chem 277,
20618–20624.
[21] Jhabvala-Romero F, Evans A, Guo S, Denton M, and Clinton GM (2003). Her-
statin inhibits heregulin-mediated breast cancer cell growth and overcomes ta-
moxifen resistance in breast cancer cells that overexpress HER-2. Oncogene 22,
8178–8186.
[22] Mullen P, Cameron DA, Hasmann M, Smyth JF, and Langdon SP (2007). Sen-
sitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen
receptor signaling. Mol Cancer Ther 6, 93–100.
[23] Nahta R, Hung MC, and Esteva FJ (2004). The HER-2–targeting antibodies
trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer
cells. Cancer Res 64, 2343–2346.
[24] Staverosky JA, Muldoon LL, Guo S, Evans AJ, Neuwelt EA, and Clinton GM
(2005). Herstatin, an autoinhibitor of the epidermal growth factor receptor fam-
ily, blocks the intracranial growth of glioblastoma. Clin Cancer Res 11, 335–340.
[25] Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, and Hung MC (2001). Cytoplas-
mic localization of p21CIP1/WAF1 by Akt-induced phosphorylation in HER-2/
neu–overexpressing cells. Nat Cell Biol 3, 245–252.
[26] Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, and
Bartlett JM (2005). AKT activation predicts outcome in breast cancer patients
treated with tamoxifen. J Pathol 207, 139–146.
[27] Vestey SB, Sen C, Calder CJ, Perks CM, Pignatelli M, and Winters ZE (2005).
Activated Akt expression in breast cancer: correlation with p53, Hdm2 and pa-
tient outcome. Eur J Cancer 41, 1017–1025.
[28] Park SS and Kim SW (2007). Activated Akt signaling pathway in invasive ductal
carcinoma of the breast: correlation with HER2 overexpression. Oncol Rep 18,
139–143.
[29] Tokunaga E, Kimura Y, Oki E, Ueda N, Futatsugi M, Mashino K, Yamamoto
M, Ikebe M, Kakeji Y, Baba H, et al. (2006). Akt is frequently activated in
HER2/neu-positive breast cancers and associated with poor prognosis among
hormone-treated patients. Int J Cancer 118, 284–289.
[30] Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, and Harris AL (2003).
Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast
cancer and is an independent predictor of prognosis. Breast Cancer Res 5,
R242–R249.
[31] Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, Zhou BP, and Hung MC
(2004). Phosphorylation/cytoplasmic localization of p21CIP1/WAF1 is associated
with HER2/neu overexpression and provides a novel combination predictor for
poor prognosis in breast cancer patients. Clin Cancer Res 10, 3815–3824.
[32] Finak G, Sadekova S, Pepin F, Hallett M, Meterissian S, Halwani F, Khetani K,
Souleimanova M, Zabolotny B, Omeroglu A, et al. (2006). Gene expression
signatures of morphologically normal breast tissue identify basal-like tumors.
Breast Cancer Res 8, R58.
[33] Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE, Lee J,
Keller GA, Li WL, Fendly BM, et al. (1993). A truncated intracellular HER2/
neu receptor produced by alternative RNA processing affects growth of human
carcinoma cells. Mol Cell Biol 13, 2247–2257.
[34] Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data
using real-time quantitative PCR and the 2(−Delta Delta C (T)) method. Meth-
ods 25, 402–408.
[35] Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, and Lidereau R (2003).
Prognostic value of ERBB family mRNA expression in breast carcinomas. Int
J Cancer 106, 758–765.
[36] Camenisch TD, Schroeder JA, Bradley J, Klewer SE, and McDonald JA (2002).
Heart-valve mesenchyme formation is dependent on hyaluronan-augmented ac-
tivation of ErbB2-ErbB3 receptors. Nat Med 8, 850–855.
[37] Fisher MC, Clinton GM, Maihle NJ, and Dealy CN (2007). Requirement for
ErbB2/ErbB signaling in developing cartilage and bone. Dev Growth Differ 49,
503–513.
[38] Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L,
and Hortobagyi GN (2004). Targeted therapy in breast cancer: the HER-2/neu
gene and protein. Mol Cell Proteomics 3, 379–398.
[39] Sweeney C, Miller JK, Shattuck DL, and Carraway KL III (2006). ErbB recep-
tor negative regulatory mechanisms: implications in cancer. Proc Natl Acad Sci
USA 101, 17138–17143.
[40] Jackson-Fisher AJ, Bellinger G, Ramabhadran R, Morris JK, Lee KF, and Stern
DF (2004). ErbB2 is required for ductal morphogenesis of the mammary gland.
Proc Natl Acad Sci USA 101, 17138–17143.
[41] Troyer KL and Lee DC (2001). Regulation of mouse mammary gland develop-
ment and tumorigenesis by the ERBB signaling network. J Mammary Gland
Biol Neoplasia 6, 7–21.
[42] Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D, Lane
N, Solomayer E, and Uhr J (2007). Determination of HER2 status using both
serum HER2 levels and circulating tumor cells in patients with recurrent breast
cancer whose primary tumor was HER2 negative or of unknown HER2 status.
Breast Cancer Res 9, R74.
[43] Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, and
Hudis C (2005). Serum HER2 extracellular domain in metastatic breast cancer
patients treated with weekly trastuzumab and paclitaxel: association with HER2
status by immunohistochemistry and fluorescence in situ hybridization and with
response rate. Ann Oncol 16, 234–239.
[44] Muller V, Witzel I, Luck HJ, Kohler G, von Minckwitz G, Mobus V, Sattler D,
Wilczak W, Loning T, Janicke F, et al. (2004). Prognostic and predictive impact of
the HER-2/neu extracellular domain (ECD) in the serum of patients treated with
chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 86, 9–18.
[45] Rampaul RS, Pinder SE, Gullick WJ, Robertson JF, and Ellis IO (2002). HER-2
in breast cancer—methods of detection, clinical significance and future prospects
for treatment. Crit Rev Oncol Hematol 43, 231–244.
[46] ADVIA Centaur HER-2/neu Assay [package insert]. Deerfield, IL: Siemens Health-
care Diagnostics Inc.; 2007–2008. Available from: http://diagnostics.siemens.com/
webapp/wcs/stores/servlet/PSGenericDisplay~q_catalogId~e_-111~a_langId~e_
-111~a_pageId~e_79003~a_storeId~e_10001.htm.
[47] Carney WP, Marks PJ, Mazzara GP, McKenzy SJ, Morgan JH, Petit DA, and
Weinberg RA. Detection and quantification of neu related proteins in the bio-
logical fluids of humans. International Patent WO/1991/005264. April 18, 1991.
OCR text available from: http://www.wipo.int/pctdb/en/wo.jsp?WO=1991%
2F05264&IA=WO1991%2F05264&DISPLAY=DESC.
[48] Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, and
Clinton GM (1998). NH2-terminally truncated HER-2/neu protein: relation-
ship with shedding of the extracellular domain and with prognostic factors in
breast cancer. Cancer Res 58, 5123–5129.
[49] Cicenas J, Urban P, Vuaroqueaux V, Labuhn M, Kung W, Wight E, Mayhew M,
Eppenberger U, and Eppenberger-Castori S (2005). Increased level of phos-
phorylated Akt measured by chemiluminescence-linked immunosorbent assay
is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-
2. Breast Cancer Res 7, R394–R401.
[50] Perez-Tenorio G, Berglund F, Esguerra Merca A, Nordenskjold B, Rutqvist LE,
Skoog L, and Stal O (2006). Cytoplasmic p21WAF1/CIP1 correlates with Akt acti-
vation and poor response to tamoxifen in breast cancer. Int J Oncol 28, 1031–1042.
[51] Stal O, Perez-Tenorio G, Akerberg L, Olsson B, Nordenskjold B, Skoog L, and
Rutqvist LE (2003). Akt kinases in breast cancer and the results of adjuvant
therapy. Breast Cancer Res 5, R37–R44.
[52] Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N,
Natesan S, and Brugge JS (2005). Distinct roles of Akt1 and Akt2 in regulating
cell migration and epithelial-mesenchymal transition. J Cell Biol 171, 1023–1034.
Neoplasia Vol. 10, No. 7, 2008 Herstatin in Breast Carcinomas Koletsa et al. 695
[53] Maroulakou IG, Oemler W, Naber SP, and Tsichlis PN (2007). Akt1 ablation
inhibits, whereas Akt2 ablation accelerates, the development of mammary ade-
nocarcinomas in mouse mammary tumor virus (MMTV)–ErbB2/neu and
MMTV-polyoma middle T transgenic mice. Cancer Res 67, 167–177.
[54] Zinda MJ, Johnson MA, Paul JD, Horn C, Konicek BW, Lu ZH, Sandusky G,
Thomas JE, Neubauer BL, Lai MT, et al. (2001). AKT-1, -2, and -3 are ex-
pressed in both normal and tumor tissues of the lung, breast, prostate, and colon.
Clin Cancer Res 7, 2475–2479.
[55] Liu W, Bagaitkar J, and Watabe K (2007). Roles of AKT signal in breast cancer.
Front Biosci 12, 4011–4019.
[56] Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, and Toker A (2005).
Akt blocks breast cancer cell motility and invasion through the transcription
factor NFAT. Mol Cell 20, 539–550.
[57] Mayo LD and Donner DB (2001). A phosphatidylinositol 3-kinase/Akt path-
way promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc
Natl Acad Sci USA 98, 11598–11603.
[58] Schmitz KJ, Grabellus F, Callies R, Wohlschlaeger J, Otterbach F, Kimmig R,
Levkau B, Schmid KW, and Baba HA (2006). Relationship and prognostic signifi-
cance of phospho-(serine 166)–murine doubleminute 2 and Akt activation in node-
negative breast cancer with regard to p53 expression. Virchows Arch 448, 16–23.
[59] Li Q, Mullins SR, Sloane BF, and Mattingly RR (2008). p21-Activated kinase 1
coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional
culture model for premalignant progression of human breast cancer. Neoplasia 10,
314–329.
[60] Perera RM, Zoncu R, Johns TG, Pypaert M, Lee FT, Mellman I, Old LJ,
Toomre DK, and Scott AM (2007). Internalization, intracellular trafficking,
and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth
factor receptor antibody. Neoplasia 9, 1099–1110.
[61] Shepard HM, Jin P, Slamon DJ, Pirot Z, and Maneval DC (2008). Herceptin.
Handb Exp Pharmacol (181), 183–219.
[62] Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR,
Wang J, Derynck MK, Ng K, Lyons B, et al. (2007). Efficacy and safety of
single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor re-
ceptor dimerization inhibitor, in castration-resistant prostate cancer after pro-
gression from taxane-based therapy. J Clin Oncol 25, 675–681.
[63] Attard G, Kitzen J, Blagden SP, Fong PC, Pronk LC, Zhi J, Zugmaier G, Verweij
J, de Bono JS, and de Jonge M (2007). A phase Ib study of pertuzumab, a re-
combinant humanised antibody to HER2, and docetaxel in patients with ad-
vanced solid tumours. Br J Cancer 97, 1338–1343.
[64] Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller
VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, et al. (2007). Efficacy
and safety of single-agent pertuzumab, a human epidermal receptor dimeriza-
tion inhibitor, in patients with non small cell lung cancer. Clin Cancer Res
13, 6175–6181.
696 Herstatin in Breast Carcinomas Koletsa et al. Neoplasia Vol. 10, No. 7, 2008
